BIO vs GKOS Stock Comparison
BIO currently leads GKOS in this stock comparison, with AIQ scores of 73 vs 65. The clearest difference is value, while GKOS has the stronger momentum profile.
What is the main difference between BIO and GKOS?
BIO leads the current stock comparison as Bio-Rad Laboratories, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Bio-Rad Laboratories, Inc. vs Glaukos Corporation
BIO leads
BIO leads by 8 AIQ points, primarily on Value and Risk Resilience.
Competitive: 3 of 5 evidence groups support BIO, and its current signal state is conflicted.
Bio-Rad Laboratories, Inc.
Glaukos Corporation
The Algovestiq AIQ Score currently favors BIO over GKOS, 73 versus 65 as of Nov 18, 2026. BIO's advantage is driven primarily by stronger value and risk resilience, while GKOS holds the stronger momentum profile. BIO also shows the weaker technical structure relative to its 50-day moving average. 3 of 5 covered evidence groups favor BIO today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. BIO lead: Stable — the AIQ differential has held near 8 points over 30 sessions.
Compare Bio-Rad Laboratories, Inc. and Glaukos Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare BIO and GKOS against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value80 vs 30BIO +50
- Risk Resilience74 vs 57BIO +17
- Momentum79 vs 90GKOS +11
- Quality61 vs 64Even
3 of 5 evidence groups favor BIO. BIO’s edge is concentrated in value and risk resilience; GKOS keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.
Largest factor move: Momentum -1, not enough on its own to move the overall score.
New signals
- MACD Bearish Crossover — bearish, momentum, short horizon
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
Largest factor move: Momentum -1
New signals
- Stochastic Overbought Rollover — bearish, momentum, short horizon
BIO's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — BIO and GKOS both carry a full feed there.
The central trade-off
BIO (Bio-Rad Laboratories, Inc.): the stronger current systematic profile, led by value and risk resilience.
GKOS (Glaukos Corporation): the counter-case, on momentum, fundamentals, technicals — but at materially higher volatility, 130.4% against 31.4%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
BIOBIO on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
GKOSGKOS on combined revenue and EPS growth.
Value
BIOBIO on the peer-relative Value factor, by 50 points.
Momentum
GKOSGKOS on the Momentum factor, by 11 points.
Lower downside
BIOBIO on Risk Resilience, by 17 points.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | BIO | GKOS | Note |
|---|---|---|---|
| Implied upside to target | — | +0.4% | Level |
| Target dispersion | — | +21.4% | Lower is tighter analyst agreement |
| Consensus | Hold | Buy | Context, not a primary driver |
| Analysts covering | 3 | 13 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 5 covered evidence groups favor BIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | BIO | 73 vs 65 |
| Fundamentals | GKOSon balance | EPS growth 23.3% vs 109.7%; gross margin 51.3% vs 81.1%; operating margin 4.6% vs -9.2% — GKOS takes 2 of 3 decided legs, not all of them |
| Valuation | BIO | Value 80 vs 30 |
| Technicals | GKOS | Price vs 50-day -0.7% vs 26.3%; vs 200-day 15.6% vs 66.9% |
| Risk Resilience | BIO | Risk Resilience 74 vs 57 |
| Analyst expectations | Not covered | Not covered |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BIO and GKOS and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is moderate at 8 points.
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BIO.
How the comparison changed
120 daily snapshots · Jun 1 – Nov 18BIO lead: Stable — the AIQ differential has held near 8 points over 30 sessions.
- Today
- BIO +8
- 73 vs 65
- 7 sessions ago
- BIO +9
- 75 vs 66
- 30 sessions ago
- BIO +10
- 72 vs 62
- 90 sessions ago
- BIO +9
- 73 vs 64
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 2 bearish / 1 neutral, conflicted
Only BIO
- MACD Bearish Crossover — bearish, momentum, short horizon
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
6 bullish / 3 bearish / 2 neutral, conflicted
Only GKOS
- 52-Week High Proximity — bullish, risk_regime, long horizon (2.4%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.29x)
- RSI Bearish Divergence — bearish, momentum, medium horizon
- Stochastic Overbought Rollover — bearish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 4 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish, TRIX Bullish Signal.
BIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +3.34%, AIQ 0 points).
Price and the AIQ Score both moved down over the latest session (price -4.18%, AIQ -1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1GKOS closes the Value gap — currently 50 points behind, the largest single contributor to BIO's edge.
- 2GKOS generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover.
- 3BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
GKOS leads on balance| Metric | BIO | GKOS |
|---|---|---|
| Revenue growth (YoY) | 0.8% | 13.7% |
| EPS growth (YoY) | 23.3% | 109.7% |
| Gross margin | 51.3% | 81.1% |
| Operating margin | 4.6% | -9.2% |
| Return on equity (TTM) | 6% | 0.3% |
| Debt to equity | 0.18 | 0.14 |
Performance
GKOS leads 6 of 6 windows| Metric | BIO | GKOS |
|---|---|---|
| 1 week (5 sessions) | -4% | 9.5% |
| 1 month (20 sessions) | 3.6% | 49.1% |
| 3 months (63 sessions) | 3.1% | 32.4% |
| 6 months (126 sessions) | 48% | 70.6% |
| Year to date | 20.9% | 117.6% |
| 1 year (252 sessions) | 11.9% | 165.3% |
Technicals
GKOS has the stronger structure| Metric | BIO | GKOS |
|---|---|---|
| RSI (14) | 45.4 | 68.7 |
| ADX (14) | 12.9 | 41.2 |
| Price vs 50-day | -0.7% | 26.3% |
| Price vs 200-day | 15.6% | 66.9% |
| Volatility (1M, annualized) | 31.4% | 130.4% |
Risk
BIO is the more resilient| Metric | BIO | GKOS |
|---|---|---|
| Beta | 0.73 | 1.06 |
| Sharpe ratio | 0.47 | 1.83 |
| Sortino ratio | 0.69 | 3.79 |
| Max drawdown | -27.2% | -28.4% |
| Current drawdown | -6.1% | -0.6% |
| Annualized volatility | 36.2% | 61.4% |
| Value at risk (95%) | -3% | -4% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, BIO or GKOS?
On the Algovestiq AIQ Score, BIO is the stronger of the two as of Nov 18, 2026, scoring 73 against GKOS's 65. The edge comes from value and risk resilience. GKOS is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is BIO or GKOS the better buy right now?
BIO carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Competitive — 3 of 5 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor BIO over GKOS?
The composite weights Quality, Value, Momentum and Risk Resilience. BIO leads Value by 50 points; BIO leads Risk Resilience by 17 points; GKOS leads Momentum by 11 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, BIO or GKOS?
Analyst price targets imply not covered upside for BIO and +0.4% for GKOS. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, BIO or GKOS?
BIO is the better-valued of the two on the peer-relative Value factor. BIO on the peer-relative Value factor, by 50 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, BIO or GKOS?
GKOS on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, BIO or GKOS?
GKOS on the Momentum factor, by 11 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, BIO or GKOS?
BIO is the more resilient of the two, so the other name carries the higher downside risk. BIO on Risk Resilience, by 17 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is BIO more profitable than GKOS?
The profitability evidence is mixed: gross margin 51.3% vs 81.1%; operating margin 4.6% vs -9.2%; ttm roe 6% vs 0.3%. Each name leads on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is BIO's lead over GKOS getting stronger or weaker?
BIO lead: Stable — the AIQ differential has held near 8 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.
What would change the BIO vs GKOS verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: GKOS closes the Value gap — currently 50 points behind, the largest single contributor to BIO's edge; GKOS generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover; BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about BIO and GKOS?
BIO: 3 bullish / 2 bearish / 1 neutral, conflicted. GKOS: 6 bullish / 3 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BIO is Golden Cross Active (bullish, long horizon). On GKOS it is Golden Cross Active (bullish, long horizon).
Compare BIO and GKOS with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.